Dosimetry of high-dose treatment with 131I in differentiated thyroid cancer -: Evaluation by PET and 124I.

被引：0
|
作者：
Eschmann, SM
Thelen, MH
Reischl, G
Zagar, I
Dohmen, BM
Coenen, HH
Machulla, HJ
Bares, R
机构：
[1] Res Ctr Julich, Julich, Germany
[2] Univ Belgrade, Belgrade, Yugoslavia
[3] Univ Tubingen, Tubingen, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2000年 / 41卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
333
引用
收藏
页码：84P / 84P
页数：1
相关论文
共 50 条
  • [1] Bone marrow radiation dosimetry of high dose 131I treatment in differentiated thyroid carcinoma patients
    Parlak, Y.
    Demir, M.
    Cavdar, I.
    Ereees, S.
    Gumuser, G.
    Uysal, B.
    Kaya, G. Capa
    Koc, M.
    Sayit, E.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2016, 14 (02): : 99 - 104
  • [2] Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer
    Doi, SAR
    Woodhouse, NJY
    CLINICAL ENDOCRINOLOGY, 2000, 52 (06) : 765 - 773
  • [3] Dosimetry clinical application in differentiated thyroid cancer treated with 131I
    Testanera, G.
    Antunovic, L.
    Tosi, G.
    Pusceddu, M.
    Leonardi, L.
    Roffinengo, C.
    Tarullo, G.
    Chiti, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S463 - S463
  • [4] Role of 131I in the treatment of well differentiated thyroid cancer
    Woodrum, DT
    Gauger, PG
    JOURNAL OF SURGICAL ONCOLOGY, 2005, 89 (03) : 114 - 121
  • [5] Low activity treatment with 131I in differentiated thyroid cancer
    Olivan-Sasot, P.
    Prado-Wohlwend, S.
    Sanchez-Vano, R.
    Yepes-Agudelo, A.
    Agudelo-Cifuentes, M.
    Bernal-Vergara, J.
    Bello-Arques, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S608 - S609
  • [6] Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma
    Verburg, Frederik A.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (03): : 253 - 257
  • [7] Can the 124I dosimetry in a patient affected by metastatic Differentiated Thyroid Cancer predict the effectivness of 131I therapy in the metastases?
    Rossi, G.
    Camarda, M.
    Montani, L.
    Brianzoni, E.
    Ancidei, S.
    Barucca, S.
    Berbellini, A.
    Capoccetti, F.
    Criscuoli, B.
    Ferretti, F.
    Manni, C.
    Nicoli, P. S.
    Remediani, S.
    Fattori, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S180 - S181
  • [8] Pretherapeutic Dosimetry in Patients Affected by Metastatic Thyroid Cancer Using 124I PET/CT Sequential Scans for 131I Treatment Planning
    Pettinato, Cinzia
    Spezi, Emiliano
    Nanni, Cristina
    Grassetto, Gaia
    Monari, Fabio
    Allegri, Vincenzo
    Civollani, Simona
    Cima, Simona
    Zagni, Paolo
    Mazzarotto, Renzo
    Colletti, Patrick M.
    Rubello, Domenico
    Fanti, Stefano
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (08) : E367 - E374
  • [9] Post-surgical ablation of thyroid remnants with high-dose 131I in patients with differentiated thyroid carcinoma
    Arslan, N
    Ilgan, S
    Serdengecti, M
    Ozguven, MA
    Bayhan, H
    Okuyucu, K
    Gulec, SA
    NUCLEAR MEDICINE COMMUNICATIONS, 2001, 22 (09) : 1021 - 1027
  • [10] Multistage High-Dose I-131 Treatment for a Nonthyroidectomized Patient With Metastatic Differentiated Thyroid Cancer
    Ahn, Byeong-Cheol
    Lee, Sang-Woo
    Lee, Jaetae
    CLINICAL NUCLEAR MEDICINE, 2011, 36 (12) : E224 - E227
12345